Navigation Links
IntegriChain Appoints John Bailye to Its Board of Directors
Date:6/2/2008

PRINCETON, N.J., June 2 /PRNewswire/ -- IntegriChain, Inc. today announced the appointment of industry veteran John Bailye to the Company's Board of Directors, further bolstering its position as a leader in the pharmaceutical information services industry.

Mr. Bailye, 54, recently retired from his position as Chairman & CEO of Dendrite International after Dendrite was acquired by French information provider Cegedim. Under Mr. Bailye's leadership, Dendrite, a pharmaceutical sales force automation system company, grew to more than 3500 employees, acquired 23 companies and generated $450 million in global sales revenue to become the leading SFA tool in the pharmaceutical industry. Throughout his career, Mr. Bailye has served on a number of not-for-profit organizations, including the New Jersey Technology Council where he was co-Founder and Board Member. Currently, Mr. Bailye is also a director, advisor and investor in Solar Centre LLC, a General Partner of the Roxiticus Life Sciences Fund.

Kevin Leininger, Chief Executive Officer of IntegriChain commented, "We are thrilled to have John join our Board of Directors. John is a seasoned executive and leader who brings a wealth of experience and proven track record in building a strong information services company in the pharmaceutical industry."

"IntegriChain has an innovative approach to helping pharmaceutical companies take more advantage of their channel data for commercial applications such as forecasting, demand validation and product launch," said Mr. Bailye. "I am excited by the sizeable potential IntegriChain represents and I look forward to leveraging my experience to help the Company expand its possibilities even further."

About IntegriChain

IntegriChain, Inc. is an information services company which provides data collection, integration, enrichment, analysis and reporting of sales and inventory activity for the pharmaceutical industry. IntegriChain enables manufacturers to improve sales performance and increase patient safety by maximizing transparency and accountability in the supply chain. IntegriChain's Enriched Channel Sales(TM) and advanced analytics are transforming the role of channel data within key pharmaceutical application areas including new product launch, sales forecasting, and demand analysis.


'/>"/>
SOURCE IntegriChain, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Appoints Paul Truex to Board of Directors
2. Pelikan Technologies Appoints Denny Ware to Board of Directors
3. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
4. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
5. Nventa Appoints Gordon H. Busenbark to Board of Directors
6. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
7. Informed Medical Communications Appoints New Chief Financial Officer
8. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):